Search

Your search keyword '"Zhao, Runchu"' showing total 11 results
Start Over Author "Zhao, Runchu" Publication Year Range Last 10 years
11 results on '"Zhao, Runchu"'

2. MD Simulation of Hundred-Billion-Metal-Atom Cascade Collision on Sunway Taihulight

Author

Chu, Genshen, Li, Yang, Zhao, Runchu, Ren, Shuai, Yang, Wen, He, Xinfu, Hu, Chungjun, and Wang, Jue

Subjects
Computer Science - Distributed, Parallel, and Cluster Computing
Abstract

Radiation damage to the steel material of reactor pressure vessels is a major threat to the nuclear reactor safety. It is caused by the metal atom cascade collision, initialized when the atoms are struck by a high-energy neutron. The paper presents MISA-MD, a new implementation of molecular dynamics, to simulate such cascade collision with EAM potential. MISA-MD realizes (1) a hash-based data structure to efficiently store an atom and find its neighbors, and (2) several acceleration and optimization strategies based on SW26010 processor of Sunway Taihulight supercomputer, including an efficient potential table storage and interpolation method, a coloring method to avoid write conflicts, and double-buffer and data reuse strategies. The experimental results demonstrated that MISA-MD has good accuracy and scalability, and obtains a parallel efficiency of over 79% in an 655-billion-atom system. Compared with a state-of-the-art MD program LAMMPS, MISA-MD requires less memory usage and achieves better computational performance.

Published
2021

4. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2

Author

Rao, Xia, primary, Zhao, Runchu, additional, Tong, Zhou, additional, Guo, Shuxin, additional, Peng, Weiyu, additional, Liu, Kefang, additional, Li, Shihua, additional, Wu, Lili, additional, Tong, Jianyu, additional, Chai, Yan, additional, Han, Pu, additional, Wang, Feiran, additional, Jia, Peng, additional, Li, Zhaohui, additional, Zhao, Xin, additional, Li, Dedong, additional, Zhang, Rong, additional, Zhang, Xue, additional, Zou, Weiwei, additional, Li, Weiwei, additional, Wang, Qihui, additional, Gao, George Fu, additional, Wu, Yan, additional, Dai, Lianpan, additional, and Gao, Feng, additional

Published
2023
Full Text
View/download PDF

5. Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections.

Author

Zhao, Runchu, Wu, Lili, Sun, Junqing, Liu, Dezhi, Han, Pu, Gao, Yue, Zhang, Yi, Xu, Yanli, Qu, Xiao, Wang, Han, Chai, Yan, Chen, Zhihai, Gao, George F., and Wang, Qihui

Subjects
MONOCLONAL antibodies, MONKEYPOX, ANIMAL experimentation, IMMUNOGLOBULINS, SMALLPOX, VACCINIA
Abstract

The recent outbreak of mpox epidemic, caused by monkeypox virus (MPXV), poses a new threat to global public health. Here, we initially assessed the preexisting antibody level to the MPXV B6 protein in vaccinia vaccinees born before the end of the immunization program and then identified two monoclonal antibodies (MAbs), hMB621 and hMB668, targeting distinct epitopes on B6, from one vaccinee. Binding assays demonstrate that both MAbs exhibit broad binding abilities to B6 and its orthologs in vaccinia (VACV), variola (VARV) and cowpox viruses (CPXV). Neutralizing assays reveal that the two MAbs showed potent neutralization against VACV. Animal experiments using a BALB/c female mouse model indicate that the two MAbs showed effective protection against VACV via intraperitoneal injection. Additionally, we determined the complex structure of B6 and hMB668, revealing the structural feature of B6 and the epitope of hMB668. Collectively, our study provides two promising antibody candidates for the treatment of orthopoxvirus infections, including mpox. There are limited therapeutics available for treatment of mpox. In this study, the authors identify two non-competing human neutralizing monoclonal antibodies with protective effects against orthopoxvirus infection in a mouse model and structurally resolve the targeted epitope within the MPXV B6 protein. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3

Author

Huang, Min, primary, Wu, Lili, additional, Zheng, Anqi, additional, Xie, Yufeng, additional, He, Qingwen, additional, Rong, Xiaoyu, additional, Han, Pu, additional, Du, Pei, additional, Han, Pengcheng, additional, Zhang, Zengyuan, additional, Zhao, Runchu, additional, Jia, Yunfei, additional, Li, Linjie, additional, Bai, Bin, additional, Hu, Ziliang, additional, Hu, Shixiong, additional, Niu, Sheng, additional, Hu, Yu, additional, Liu, Honghui, additional, Liu, Bo, additional, Cui, Kaige, additional, Li, Weiwei, additional, Zhao, Xin, additional, Liu, Kefang, additional, Qi, Jianxun, additional, Wang, Qihui, additional, and Gao, George Fu, additional

Published
2022
Full Text
View/download PDF

7. Cross-species recognition and molecular basis of SARS-CoV-2 and SARS-CoV binding to ACE2s of marine animals

Author

Li, Shihua, primary, Yang, Ruirui, additional, Zhang, Di, additional, Han, Pu, additional, Xu, Zepeng, additional, Chen, Qian, additional, Zhao, Runchu, additional, Zhao, Xin, additional, Qu, Xiao, additional, Zheng, Anqi, additional, Wang, Liang, additional, Li, Linjie, additional, Hu, Yu, additional, Zhang, Rong, additional, Su, Chao, additional, Niu, Sheng, additional, Zhang, Yanfang, additional, Qi, Jianxun, additional, Liu, Kefang, additional, Wang, Qihui, additional, and Gao, George F, additional

Published
2022
Full Text
View/download PDF

8. Atlas of Currently-Available Human MAbs and Escape to Newly-Emerging Omicron BA.1/BA.1.1/BA.2/BA.3

Author

Huang, Min, primary, Wu, Lili, additional, Zheng, Anqi, additional, Xie, Yufeng, additional, He, Qingwen, additional, Rong, Xiaoyu, additional, Han, Pu, additional, Du, Pei, additional, Han, Pengcheng, additional, Zhang, Zengyuan, additional, Zhao, Runchu, additional, Jia, Yunfei, additional, Li, Linjie, additional, Bai, Bin, additional, Hu, Ziliang, additional, Hu, Shixiong, additional, Niu, Sheng, additional, Hu, Yu, additional, Liu, Honghui, additional, Liu, Bo, additional, Cui, Kaige, additional, Li, Weiwei, additional, Zhao, Xin, additional, Liu, Kefang, additional, Qi, Jianxun, additional, Wang, Qihui, additional, and Gao, George F., additional

Published
2022
Full Text
View/download PDF

10. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses

Author

Zhou, Hong, primary, Ji, Jingkai, additional, Chen, Xing, additional, Bi, Yuhai, additional, Li, Juan, additional, Wang, Qihui, additional, Hu, Tao, additional, Song, Hao, additional, Zhao, Runchu, additional, Chen, Yanhua, additional, Cui, Mingxue, additional, Zhang, Yanyan, additional, Hughes, Alice C., additional, Holmes, Edward C., additional, and Shi, Weifeng, additional

Published
2021
Full Text
View/download PDF

11. Cross-species recognition of bat coronavirus RsYN04 and cross-reaction of SARS-CoV-2 antibodies against the virus.

Author

Zhao R, Niu S, Han P, Gao Y, Liu D, Luo C, Liu H, Liu B, Xu Y, Qi J, Chen Z, Shi W, Wu L, Gao GF, and Wang Q

Subjects
Animals, Humans, SARS-CoV-2, Angiotensin-Converting Enzyme 2, Antibodies, Viral, Epitopes, COVID-19 veterinary, Chiroptera genetics
Abstract

Following the outbreak of coronavirus disease 2019 (COVID-19), several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronaviruses have been discovered. Previous research has identified a novel lineage of SARS-CoV-2-related CoVs in bats, including RsYN04, which recognizes human angiotensin-converting enzyme 2 (ACE2) and thus poses a potential threat to humans. Here, we screened the binding of the RsYN04 receptor-binding domain (RBD) to ACE2 orthologs from 52 animal species and found that the virus showed a narrower ACE2-binding spectrum than SARS-CoV-2. However, the presence of the T484W mutation in the RsYN04 RBD broadened its range. We also evaluated 44 SARS-CoV-2 antibodies targeting seven epitope communities in the SARS-CoV-2 RBD, together with serum obtained from COVID-19 convalescents and vaccinees, to determine their cross-reaction against RsYN04. Results showed that no antibodies, except for the RBD-6 and RBD-7 classes, bound to the RsYN04 RBD, indicating substantial immune differences from SARS-CoV-2. Furthermore, the structure of the RsYN04 RBD in complex with cross-reactive antibody S43 in RBD-7 revealed a potently broad epitope for the development of therapeutics and vaccines. Our findings suggest RsYN04 and other viruses belonging to the same clade have the potential to infect several species, including humans, highlighting the necessity for viral surveillance and development of broad anti-coronavirus countermeasures.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results